
March 11 (Reuters) - Arvinas Inc ARVN.O:
ARVINAS AND PFIZER ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERITAC-2 CLINICAL TRIAL
ARVINAS INC - VERITAC-2 ACHIEVES PRIMARY ENDPOINT IN ESR1M POPULATION
ARVINAS INC - TRIAL DID NOT REACH STATISTICAL SIGNIFICANCE IN ITT POPULATION
ARVINAS INC - VEPDEGESTRANT GENERALLY WELL TOLERATED WITH CONSISTENT SAFETY PROFILE
ARVINAS INC - TRIAL TO CONTINUE ASSESSING OVERALL SURVIVAL AS SECONDARY ENDPOINT